Keyword: Medicare Payment Advisory Commission (MedPAC)
Updated Jan. 29: The feds aren't doing a good job of determining whether a drug company has to provide both 340B discounts and rebates for Medicaid.
340B hospitals spent slightly more on cancer drugs on average compared to hospitals not in the program, a new analysis finds.
MedPAC wants to give hospitals a 3.3% Medicare payment boost in 2021, devoting some of that boost to quality programs.
Medicare Advantage rebates to plans are expected to reach historic highs next year, MedPAC analysis finds.
Hospitals got $201 billion in Medicare fee-for-service payments in 2018, a 3.6% increase from 2017, a new analysis found.
Medicare's payment policy is driving hospital-physician mergers even if the merger doesn't improve quality, MedPAC found.
Medicare cut payments to 2,583 hospitals, continuing the Affordable Care Act’s campaign to financially pressure hospitals into reducing readmissions.
A new study found a nixed CMS proposal to give Part D plans more flexibility to drop protected-class drugs could have hampered patient access.
More brand-name discounts for drugs offered in Part D's "doughnut hole" could inadvertently stymie generic competition, a new Health Affairs study says.
MedPAC is urging Congress to adopt reforms to improve the quality of encounter data and boost beneficiaries’ access to primary care.